503b listing
Semaglutide Vs 503B - Hidden Exclusion Explosion
The FDA’s April 30 proposal removes semaglutide and tirzepatide from the 503B bulk list, forcing compounding pharmacies to change how they obtain these GLP-1 drugs. This shift pushes clinics toward wholesale distributors or 503A-registered facilities, raising costs and altering delivery timelines. Medical Disclaimer: This article is for informational purposes